Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Associate Professor Michael Tatley

PositionResearch Associate Professor
QualificationsMB ChB(CapeTown) FFCM(SA)
Research summaryMonitoring adverse reactions medicines

Research

Director of the New Zealand Pharmacovigilance Centre

The New Zealand Pharmacovigilance Centre consists of the Centre for Adverse Reactions Monitoring (CARM) and the The Intensive Medicines Monitoring Programme (IMMP).

Adverse reaction reporting is an important component of New Zealand's pharmacovigilance activities. The Centre for Adverse Reactions Monitoring (CARM) in Dunedin is New Zealand's national monitoring centre for adverse reactions. It collects and evaluates spontaneous reports of adverse reactions to medicines, vaccines, herbal products and dietary supplements from health professionals in New Zealand. Currently the CARM database holds over 50 000 reports and provides New Zealand-specific information on adverse reactions to these products, and serves to support clinical decision making when unusual symptoms are thought to be therapy related.

The Intensive Medicines Monitoring Programme undertakes prospective, observational, cohort studies on selected new medicines. These are aimed at measuring the incidence of adverse reactions, their characterisation, the early identification of previously unrecognised reactions and the construction of a risk profile for each medicine. The results are reported to the Ministry of Health and the health professions. It has a considerable international reputation.

Publications

Bennett, M., Chang, C. L., Tatley, M., Savage, R., & Hancox, R. J. (2021). The safety of cardio-selective beta1-blockers in asthma: Literature review and search of global pharmacovigilance safety reports. ERJ Open Research. Advance online publication. doi: 10.1183/23120541.00801-2020

Robson, H., Braund, R., Glass, M., Ashton, J., & Tatley, M. (2020). Synthetic cannabis: Adverse events reported to the New Zealand Pharmacovigilance Centre. Clinical Toxicology. Advance online publication. doi: 10.1080/15563650.2020.1828592

Savage, R. L., Hill, G. R., Barnes, J., Kenyon, S. H., & Tatley, M. V. (2019). Suspected hepatotoxicity with a supercritical carbon dioxide extract of Artemisia annua in grapeseed oil used in New Zealand [Brief research report article]. Frontiers in Pharmacology, 10, 1448. doi: 10.3389/fphar.2019.01448

Savage, R. L., & Tatley, M. V. (2018). Case series analysis of New Zealand reports of rapid intense potentiation of warfarin by roxithromycin [Short communcation]. Drug Safety, 41(5), 515-521. doi: 10.1007/s40264-017-0634-y

Savage, R. L., Castellano, M., & Tatley, M. V. (2017). International reports of unexpected low plasma concentrations of dabigatran suggest that more frequent measurements will add value. Seminars in Thrombosis & Hemostasis, 43(6), 635-638. doi: 10.1055/s-0037-1603361

Ministry of Health, including Chambers, S., Jennings, L., & Tatley, M. (2006). Immunisation Handbook 2006. Wellington, New Zealand: Ministry of Health, 455p.

Authored Book - Research

Harrison-Woolrych, M., Tatley, M., & Kunac, D. (2014). Pharmacovigilance in New Zealand. In E. B. Andrews & N. Moore (Eds.), Mann's pharmacovigilance. (3rd ed.) (pp. 291-294). Chichester, UK: Wiley Blackwell. doi: 10.1002/9781118820186.ch16a

Chapter in Book - Research

Robson, H., Braund, R., Glass, M., Ashton, J., & Tatley, M. (2020). Synthetic cannabis: Adverse events reported to the New Zealand Pharmacovigilance Centre. Clinical Toxicology. Advance online publication. doi: 10.1080/15563650.2020.1828592

Journal - Research Article

Kunac, D. L., Tatley, M. V., & Seddon, M. E. (2014). A new web-based Medication Error Reporting Programme (MERP) to supplement pharmacovigilance in New Zealand: Findings from a pilot study in primary care. New Zealand Medical Journal, 127(1401). Retrieved from http://www.nzma.org.nz/journal

Journal - Research Article

Holst, J., Oster, P., Arnold, R., Tatley, M. V., Næss, L. M., Aaberge, I. S., … Black, S. (2013). Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future. Human Vaccines & Immunotherapeutics, 9(6), 1241-1253. doi: 10.4161/hv.24129

Journal - Research Article

Kunac, D. L., & Tatley, M. V. (2011). Detecting medication errors in the New Zealand Pharmacovigilance Database: A retrospective analysis. Drug Safety, 34(1), 59-71. doi: 10.2165/11539290-000000000-00000

Journal - Research Article

Kunac, D. L., Harrison-Woolrych, M., & Tatley, M. V. (2008). Pharmacovigilance in New Zealand: The role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use. New Zealand Medical Journal, 121(1283). Retrieved from http://journal.nzma.org.nz/journal/121-1283/3286/content.pdf

Journal - Research Article

Tatley, M. V., Kunac, D. L., McNicholas, A., Zhou, L., Ballantyne, S., Ashton, J., … Reid, S. (2008). The Intensive Vaccines Monitoring Programme (IVMP): An electronic system to monitor vaccine safety in New Zealand. Vaccine, 26(22), 2746-2752. doi: 10.1016/j.vaccine.2008.03.017

Journal - Research Article

McNicholas, A., Galloway, Y., Stehr-Green, P., Reid, S., Radke, S., Sexton, K., … Tatley, M., … O'Hallahan, J. (2007). Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006. Human Vaccines, 3(5), 196-204.

Journal - Research Article

Tatley, M., & Savage, R. (2007). Psychiatric adverse reactions with statins, fibrates and ezetimibe: Implications for the use of lipid-lowering agents. Drug Safety, 30(3), 195-201.

Journal - Research Article

Tatley, M. (2002). Pulmonary reactions with nitrofurantoin. Medsafe Prescriber Update, 23(2), 24-25.

Journal - Research Article

Tatley, M. V. (2002). The monitoring of adverse events following immunisation. New Zealand Medical Journal, 115(1165).

Journal - Research Article

Zwarenstein, M., Schoeman, J. H., Vandule, C., Lombard, C. J., & Tatley, M. (1998). Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet, 352(9137), 1340-1343.

Journal - Research Article

Bennett, M., Chang, C. L., Tatley, M., Savage, R., & Hancox, R. J. (2021). The safety of cardio-selective beta1-blockers in asthma: Literature review and search of global pharmacovigilance safety reports. ERJ Open Research. Advance online publication. doi: 10.1183/23120541.00801-2020

Journal - Research Other

Savage, R. L., Hill, G. R., Barnes, J., Kenyon, S. H., & Tatley, M. V. (2019). Suspected hepatotoxicity with a supercritical carbon dioxide extract of Artemisia annua in grapeseed oil used in New Zealand [Brief research report article]. Frontiers in Pharmacology, 10, 1448. doi: 10.3389/fphar.2019.01448

Journal - Research Other

Savage, R. L., & Tatley, M. V. (2018). Case series analysis of New Zealand reports of rapid intense potentiation of warfarin by roxithromycin [Short communcation]. Drug Safety, 41(5), 515-521. doi: 10.1007/s40264-017-0634-y

Journal - Research Other

Savage, R. L., Castellano, M., & Tatley, M. V. (2017). International reports of unexpected low plasma concentrations of dabigatran suggest that more frequent measurements will add value. Seminars in Thrombosis & Hemostasis, 43(6), 635-638. doi: 10.1055/s-0037-1603361

Journal - Research Other

Kunac, D., Tatley, M. V., Grimwood, K., & Reith, D. M. (2012). Active surveillance of serious adverse drug reactions in New Zealand children. Archives of Disease in Childhood, 97(8), 761-762. doi: 10.1136/archdischild-2011-301457

Journal - Research Other

Tatley, M. (2009). Monitoring of generic medicines and brand changes. Best Practice Journal, (July), 18-20.

Journal - Research Other

Barnes, J., & Tatley, M. (2007). Scant reporting on CAMs safety in NZ. Pharmacy Today, (February), 6.

Journal - Research Other

Savage, R., & Tatley, M. (2004). Myopathy with statins: Check CK levels and interactions. Prescriber Update, 25(1), 4-5.

Journal - Research Other

Zwarenstein, M., Shoeman, J. H., Vundule, C., Lombard, C. J., & Tatley, M. V. (2000). A randomised controlled trial of lay health workers as direct observers for treatment of tuberculosis. International Journal of Tuberculosis & Lung Disease, 4(6), 550-554.

Journal - Research Other

More publications...